Russell Investments Group Ltd. boosted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 17.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 385,351 shares of the company’s stock after buying an additional 56,286 shares during the period. Russell Investments Group Ltd. owned 0.38% of Neurocrine Biosciences worth $54,391,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Entrust Financial LLC increased its stake in shares of Neurocrine Biosciences by 62.9% in the 3rd quarter. Entrust Financial LLC now owns 202 shares of the company’s stock worth $29,000 after acquiring an additional 78 shares during the last quarter. Raleigh Capital Management Inc. raised its holdings in shares of Neurocrine Biosciences by 561.8% during the 3rd quarter. Raleigh Capital Management Inc. now owns 225 shares of the company’s stock worth $32,000 after acquiring an additional 191 shares during the period. Basecamp Wealth Advisors LLC raised its holdings in shares of Neurocrine Biosciences by 582.9% during the 1st quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock worth $31,000 after acquiring an additional 204 shares during the period. Cassaday & Co Wealth Management LLC purchased a new position in shares of Neurocrine Biosciences during the 1st quarter worth $33,000. Finally, TrinityBridge Ltd acquired a new position in shares of Neurocrine Biosciences during the 2nd quarter valued at about $45,000. Institutional investors and hedge funds own 92.59% of the company’s stock.
Neurocrine Biosciences Price Performance
NASDAQ:NBIX opened at $167.40 on Monday. Neurocrine Biosciences, Inc. has a 52 week low of $122.14 and a 52 week high of $186.12. The company has a market capitalization of $16.94 billion, a P/E ratio of 24.84, a P/E/G ratio of 0.68 and a beta of 0.36. The stock’s fifty day moving average is $148.58 and its two-hundred day moving average is $148.91.
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last announced its quarterly earnings results on Monday, November 2nd. The company reported $3.29 EPS for the quarter, beating the consensus estimate of $1.91 by $1.38. The business had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.04 billion. Neurocrine Biosciences had a return on equity of 23.39% and a net margin of 18.98%. The company’s quarterly revenue was up 41.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.04 EPS. Sell-side analysts anticipate that Neurocrine Biosciences, Inc. will post 8.41 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, insider David Boyer sold 826 shares of the business’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $157.45, for a total value of $130,053.70. Following the sale, the insider directly owned 8,722 shares in the company, valued at approximately $1,373,278.90. The trade was a 8.65% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Matt Abernethy sold 2,311 shares of the company’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $157.20, for a total transaction of $363,289.20. Following the completion of the transaction, the chief financial officer directly owned 42,808 shares in the company, valued at $6,729,417.60. The trade was a 5.12% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 18,137 shares of company stock valued at $2,829,332. 4.60% of the stock is currently owned by insiders.
Analyst Ratings Changes
A number of equities research analysts recently issued reports on the stock. Zacks Research lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 4th. Wedbush raised their price objective on shares of Neurocrine Biosciences from $185.00 to $194.00 and gave the stock an “outperform” rating in a research report on Monday, August 3rd. Guggenheim lifted their target price on shares of Neurocrine Biosciences from $207.00 to $224.00 and gave the stock a “buy” rating in a research note on Wednesday, November 4th. BMO Capital Markets reduced their target price on shares of Neurocrine Biosciences from $164.00 to $150.00 and set a “market perform” rating on the stock in a research note on Monday, October 12th. Finally, Piper Sandler boosted their target price on shares of Neurocrine Biosciences from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Tuesday, November 3rd. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $202.59.
View Our Latest Report on Neurocrine Biosciences
About Neurocrine Biosciences
Neurocrine Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for neurological, endocrine and related disorders. Founded in 1992 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations. Its marketed medicines include INGREZZA (valbenazine), approved in the United States for tardive dyskinesia and chorea associated with Huntington disease, and CRENESSITY (crinecerfont), used with glucocorticoid replacement therapy to treat classic congenital adrenal hyperplasia in adults and children.
Featured Articles
- Five stocks we like better than Neurocrine Biosciences
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report).
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
